Form 8-K - Current report:
SEC Accession No. 0001628280-23-018552
Filing Date
2023-05-17
Accepted
2023-05-17 07:09:51
Documents
13
Period of Report
2023-05-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prme-20230517.htm   iXBRL 8-K 36864
2 EX-99.1 a05-17x2023xpressrelease.htm EX-99.1 27798
  Complete submission text file 0001628280-23-018552.txt   213430

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20230517.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20230517_lab.xml EX-101.LAB 24832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20230517_pre.xml EX-101.PRE 13053
7 EXTRACTED XBRL INSTANCE DOCUMENT prme-20230517_htm.xml XML 12719
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 23929617
SIC: 2836 Biological Products, (No Diagnostic Substances)